Loncastuximab Tesirine Plus Rituximab Demonstrates Efficacy and Tolerability for Treatment of R/R Follicular Lymphoma

Loncastuximab tesirine in combination with rituximab demonstrated clinically meaningful efficacy and tolerability among patients with relapsed/refractory (R/R) follicular lymphoma (FL), with a manageable safety profile, according to results from a phase 2 trial published in The Lancet Haematology.

Researchers aimed to evaluate the utilization of loncastuximab tesirine plus rituximab as a second-line treatment for patients with R/R FL who received at least 1 line of prior treatment and who had progression within 24 months in a single-arm, investigator-initiated trial.

The primary end point was complete response (CR) rate at week 12 following intimal treatment of loncastuximab tesirine with rituximab then rituximab only after a CR or a partial response (PR) was met. Overall, 39 patients with R/R FL were enrolled, and the median age was 68 years (IQR, 58 to 77). All patients met at least 1 Groupe d'Etude des Lymphomes Folliculaires (GELF) criterion (92%), and 51% had had disease progression within 24 months after firstline treatment. The median follow-up was 18.2 months (95% confidence interval [CI], 12.0 to 19.3). At 12 weeks, the CR rate at was 67%.

Regarding safety, the most common treatment-emergent adverse events of grade 3 or higher included lymphopenia (21%) and neutropenia (13%). Lower grade adverse events were generalized and peripheral oedema, and serious adverse events occurred in 10% of patients.

"Loncastuximab tesirine with rituximab showed clinically meaningful activity in relapsed or refractory follicular lymphoma, and had a manageable safety profile," the researchers concluded.

Source:

Alderuccio JP, Alencar AJ, Schatz JH, et al. Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial. The Lancet Haematology. Published online January 12, 2025. doi: 10.1016/s2352-3026(24)00345-4